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Introduction
Pancreatic cancer is one of the most lethal cancers worldwide and increasingly common (1) (2) (3) . Most patients present with advanced and thus incurable disease and die within a year of the initial diagnosis (3, 4) . There is an imminent need to identify these patients earlier in the disease process, as patients with resectable, non-metastatic cancer can potentially be cured. For many cancers it takes several years for a local malignant lesion to progress to fully metastasized disease, and pancreatic cancer is no exception (5) . Thus, there should be a window of opportunity for timely detection and intervention. Unfortunately, for early, presymptomatic pancreatic cancer currently no specific biomarkers are available. The identification of predictive biomarkers is complicated by the low incidence rate of the disease, estimated at 7-12 cases per 100,000 adult person years in the Western European population (6, 7) .
It is well known that the development and progression of pancreatic cancer are associated with alterations in systemic metabolism. Patients may present with glucose intolerance, anorexia and severe weight loss (3, 8) . In line with this, circulating metabolites have been proposed as a potentially useful screening tool in pancreatic cancer (9) (10) (11) (12) (13) (14) (15) (16) . The study by Mayers et al. (11) stood out from other metabolomic biomarker studies, as they analyzed blood samples taken two to more than ten years prior to diagnosis. They found an elevation of circulating branched-chain amino acids as an early event in the development of pancreatic cancer (11) .
Considering these preliminary predictive metabolomics biomarkers as promising, we set out to replicate these findings independently in five large European population cohorts and find additional biomarkers, using a different platform, proton nuclear magnetic resonance ( 1 H-NMR) instead of liquid chromatography followed by mass spectrometry (LC-MS).
Methods

Study Population
Our study population consisted of pancreatic cancer cases and controls, drawn from five national European cohorts, collaborating in the Biobanking and BioMolecular resources Research Infrastructure Large Population Cohorts (BBMRI-LPC; www.bbmri-lpc-biobanks.eu) and the crossinfrastructure project CORBEL (www.corbel-project.eu): the Estonian Genome Center of the University of Tartu study (EGCUT), the FINRISK Study (FR), the Nord-Trøndelag health study (HUNT2 and HUNT3), and the Rotterdam Study (RS).
EGCUT is a volunteer-based sample of the Estonian resident adult population aged 18 years and above, started in 1999 and currently has close to 52,000 participants (17) . persons who were selected to more than one independent survey by chance. Follow-up is carried out through record linkages to national administrative registers (such as the Causes of Death Register and Cancer Register), by using a unique personal identity code (19) . Register), by using a unique personal identity code (20) .
The RS is an ongoing, population-based cohort study in a suburban area of Rotterdam, the Netherlands. It was initiated in 1989 and has enrolled 14,926 individuals of 45 years and older since then. Follow-up is carried out continuously (21, 22) .
All participants of the respective cohorts provided a written informed consent. The present study was approved by the local ethics committee of each study.
Selection of cases and controls
We included incident pancreatic cancer cases, confirmed by pathology, and diagnosed after blood collection. Cases were identified through national cancer registries and through independent review of medical records. For diagnosis of pancreatic cancer, we used the ICD-10 C25.0 code.
Deaths were ascertained through the national registries. We excluded cases that lived more than 5 years after diagnosis, to avoid false positive diagnoses (23) (24) (25) .
For each case, we selected two (in RS one, in EGCUT four) random controls, matching on cohort, gender, age (± 2 years), and time of blood collection. Controls were those who were alive, without a diagnosis of pancreatic cancer at time of the case's diagnosis date.
Ascertainment of other covariates
The following covariate data were obtained from questionnaires and physical examination before blood collection: body mass index (BMI; kg/m²), smoking status (current/former/never), type 2 diabetes mellitus (T2DM) status, and fasting status (<4h/4-8h/>8h).
Metabolite profiling and quality control
Metabolites were quantified from EDTA-plasma (EGCUT) or serum (HUNT2, HUNT3, FR, RS) samples using a high-throughput Metabolite measures that failed quality control (in particular for glutamine, pyruvate, glycerol, hydroxybutyrate, and acetate) were excluded from the analysis on a per-individual basis.
One metabolite measure (glycerol) with >10% missing values was excluded entirely, resulting in a final number of 146 metabolite measures and 79 ratios. Outliers (>5 SD) were removed in concordance with previous research in this field (27) .
Statistical analysis
Differences in baseline characteristics between cases and controls were assessed for each cohort separately using Student's t-tests and ANOVAs.
Metabolite measurements were raised by one to allow log-transformation. Thereafter all metabolite values were log-transformed and scaled to obtain unit standard deviation for each cohort. They were included as continuous variables in logistics regression models and adjusted for matching factors (gender and age, minimally adjusted model). In our main model on the pooled data from all the cohorts, we additionally adjusted for BMI, smoking status, T2DM status, fasting status, and cohort. P-values were corrected for multiple testing using Westfall and Young's family-wise error rate, an appropriate method given the strong correlations between the measurements of the different metabolites (28) . To provide estimates of effect magnitude, significant metabolites were again examined in logistic regression models after categorization in quintiles. Quintiles were generated based on the metabolite values in controls only. Results were presented as odds ratios (ORs) and 95% confidence intervals (CIs).
As an alternative for the pooling of the data from the different cohorts, we also performed a logistic regression per cohort (with gender, age, BMI, smoking status, T2DM, and fasting status as covariates) and a subsequent meta-analysis. The obtained estimates for the metabolite measures and their standard errors were used in a random effects meta-analysis using the R-package meta 4.9.2 (29) . A random effects model was chosen to account for possible heterogeneity due to differences in disease assessment, sample processing, and sample collection between cohorts.
Heterogeneity was assessed using the I²-statistic and by visual inspection of forest plots. P-values from the meta-analysis were corrected for multiple-testing using Bonferroni-Holm.
Lasso regression to evaluate additive effect of metabolomics biomarkers on top of clinical predictors
To select biomarkers with predictive value, we applied a 5-fold cross-validated penalized lasso regression with the penalized package version 0.9-51 (30) . The clinical covariates (gender, age, BMI, smoking status, T2DM status, fasting status, and cohort) were not penalized and thus always present in the model. We performed a stratified analysis, including all controls but only cases who developed pancreatic cancer within 2 years or within 5 years after blood sampling or including all cases. For the variable selection, the data were split randomly into a dataset for variable selection (70% of the data; with 35% for training and 35% for cross-validation) and a dataset for performance testing (30% of the data). We compared the performance of the null model (with only the clinical covariates) with the model that included the selected metabolites using an ordinary least squares regression model. The performance of the different model was assessed by evaluating the area under the receiver operator curve (AUC).
General
Analyses were performed using the software packages meta 4.9-2, Penalized 0.9-51, 
Results
Study population and measurements
Cross-checking of the individuals in the five population cohorts included in this study with the national cancer registries enabled us to identify 444 prediagnostic samples from subjects who received diagnosis of pancreatic cancer between 1 month and 17 years after blood sampling (median 4.68 years). We subsequently selected 1,012 gender-and age-matched controls from the same cohorts ( Figure 1) . Baseline characteristics for all cohorts are shown in Table 1 . Although baseline characteristics differed significantly between cohorts (in particular for gender, BMI, T2DM, and fasting status), cases and controls did not differ in these characteristics within a cohort. We reliably quantified 146 blood metabolites and 79 metabolite ratios. Figure 1 shows the number of participants remaining after quality control and after assessment of the completeness of phenotype information in the different analyses performed.
Single-metabolite logistic regression
To identify metabolite biomarkers potentially associated with future pancreatic cancer diagnosis, we performed a separate logistic regression for each metabolite measured. In our primary model, we adjusted for the following covariates: gender, age, BMI, smoking status, T2DM status, fasting status, and cohort. The results of our top metabolites are presented in Table 2 . Full data are provided in the Supplementary Table 1 . Two metabolites demonstrated lower blood levels in cases than in controls and nominal significance: glutamine (p=0.012) and histidine (p=0.011). They were not significant after adjustment for multiple testing (Westfall-Young family-wise error rate adjusted p-value 0.43 for both metabolites). A closer inspection of the levels of glutamine and histidine, revealed that the differences were consistently observed across cohorts (Figure 2A,E) , except for glutamine in RS and histidine in FR. Glutamine levels were lower in both non-diabetics and diabetics, whereas lower histidine levels were mainly observed in pancreatic cancer that were also diagnosed with T2DM ( Figure 2B) . Histidine levels were lower in individuals who developed pancreatic cancer within 2 years after blood sampling, whereas glutamine levels were decreased longer before diagnosis ( Figure 2C,G) . Histidine levels were lower in both fasting and non-fasting individuals ( Figure 2H) , whereas the effect of fasting status on glutamine levels is difficult to ascertain given the differences between cohorts in fasting status ( Figure 2D Table 2 ). Glutamine and histidine were still among the top hits, with p-values of 0.0063 and 0.00045 (not adjusted for multiple testing), respectively.
To further address potential cohort differences, we performed a meta-analysis on the beta coefficients from the logistic regression models that were applied per cohort. The results are summarized in Table 3 and provided in full in Supplementary Table 3 . The results from the metaanalysis corroborated our findings on the pooled data, with lower glutamine levels seen for all cohorts (unadjusted p-value 0.0040), but most prominently in HUNT3 ( Figure 3A) , and lower histidine levels mostly in HUNT3 and EGCUT (unadjusted p-value 0.0022) ( Figure 3B , with similar trends in other cohorts and evidence for significant heterogeneity between cohorts). The metaanalysis provided some evidence for the involvement of omega-3 fatty acids (FAw3, including docosahexaenoic acid (DHA)) and high density lipoproteins (HDL).
To provide a better understanding of the risks associated with lower glutamine or histidine levels, we stratified the cohorts in quintiles based on the glutamine or histidine levels in controls.
Individuals within the lowest 20% of glutamine levels ran a 1.5 times elevated risk of pancreatic cancer and individuals within the lowest 20% of histidine levels ran a 2.2 times elevated risk of pancreatic cancer ( Table 4) .
Lasso regression
Lasso regression was used to evaluate the additional predictive effect of metabolomics biomarkers over clinical predictors. The performance of a reference (null) model, in which only the clinical covariates were used for prediction, was compared with an alternative model, in which metabolites selected by the lasso regression were added to the model. The cases were stratified according to the time until diagnosis (up to 2 years, up to 5 years and all cases without temporal constraint). In the model with cases up to 2 years until diagnosis, the lasso regression selected medium very low-density lipoprotein (VLDL), total unsaturated fatty acids and saturated fatty acids to be included in the model ( Table 5 ), but it did not affect the performance on the 30% of the data that were unseen during the selection of the metabolites. In the model with cases up to 5 years until diagnosis, the lasso regression model selected small VLDL and glutamine (consistent with the prominent decrease of glutamine levels in cases between 2 and 5 years before diagnosis) ( Table 5 ).
The performance of the alternative model increased slightly for both the training (AUC = 0.72 vs 0.71 for the null model, Figure 4A ) and the validation set (AUC=0.64 vs 0.62 for the null model, Figure   4B ). In the model with all cases included, more metabolites were selected ( Table 5 ), but the performance of the model including the metabolites on both training and validation set (AUC of 0.68 and 0.62, respectively) was worse than for the model with cases up to 5 years.
Discussion
Pancreatic cancer is usually diagnosed in an advanced stage of the disease, resulting in a poor prognosis. Most pancreatic cancer biomarker studies executed until today (9, 10, (13) (14) (15) (16) collected samples at the time of diagnosis or even later, and therefore have limited clinical utility.
However, they may provide insight in the pathophysiology of the disease. The setup of our study allowed for the identification of prospective biomarkers, and made efficient use of the large scale biobanking infrastructure in Europe (BBMRI-LPC program).
We identified two of these potentially, prognostic biomarkers, glutamine and histidine, while noting that the clinical utility of these biomarkers is currently low. They did not reach significance after multiple testing correction was taken into account and it is therefore possible that these hits are false positives. The increased risk of pancreatic cancer associated with low levels of glutamine and histidine was only 1.5 -2.2-fold and do not add much in terms of predictive potential to wellknown risk factors for pancreatic cancer such as age, smoking and T2DM. However, also earlier studies provided evidence for alterations in glutamine and histidine in pancreatic cancer (10, 15, 16) suggesting that these may indeed be associated with pancreatic cancer-associated changes in metabolism. In the largest study by Fukutake et al. (15) (N=360 vs 8372) , histidine was found particularly low in patients with resectable disease stage 0-IIB. This group of patients in a relatively early state of the disease is likely most similar to our group of individuals whom were diagnosed in less than two years after blood sampling and had the lowest histidine levels of all cases. Also in other cancer-related studies, negative correlations between histidine levels and cancer incidence and/or cancer-associated mortality were observed (31) (32) (33) . Remarkably, a recent report demonstrated also lower efficacy of cancer treatment in individuals with low histidine levels, and suggested histidine supplementation to enhance the efficacy of methotrexate treatment in leukemia (34) .
One of the reasons why changes in metabolites like glutamine and histidine are difficult to detect is that the concentrations of these metabolites are relatively high, and that local events like a pancreatic tumor, contribute only little to the overall pool of these metabolites. Other metabolites may be more specific to the metabolism in the pancreas and may show more prominent changes.
This type of metabolites require broader metabolomic screening than the Nightingale platform provides. While having superior robustness and throughput and low cost, the range of metabolites measured on the Nightingale platform is limited to amino acids, other polar metabolites, and a large range of lipid and lipoprotein classes. Our study calls for the use of complementary biomarker platforms on these samples, and suggests to limit the sampling to within 5 years before diagnosis and not beyond.
Our study was not able to replicate the findings from the single study with a design and sample size comparable to ours (11) . This study identified the branched chain amino acids valine, leucine, and isoleucine as potential prognostic biomarkers for pancreatic cancer. We did not find any difference between cases and controls for these amino acids nor were our top metabolites identified in this earlier study. This may be a reflection of the limited power of both studies for the discovery of small changes observed for these metabolites. However, we did not even observe trends in the same directions. Differences in the measurement platforms ( 1 H-NMR vs. LC-MS) may play a role, but the different amino acids can robustly be measured by both. It is equally plausible that the differences are due to differences in the studied populations or confounding factors, which were not or were incompletely corrected for in the statistical model, such as nutrition.
In conclusion, our study lends initial support to the existence of metabolic alterations in early pancreatic cancer development, highlighting glutamine and histidine as metabolites of interest, but also underscores the challenges to find robust, prognostic biomarkers for rare disorders. To address this, larger studies are needed, including more metabolites with lower concentrations, and/or integrated studies at multiple -omics levels. particles; M.HDL.C: total cholesterol in medium-sized HDL particles; M.HDL.CE: cholesterol esters in medium-sized HDL particles; DHA: docosahexaenoic acid. 
